top of page

Optimizing Cell Therapy to Defeat Cancer

We combine precision stem cell engineering and NK-activating antibodies to unlock the full potential of Natural Killer cells as a first line of defense against cancer.

Home: Welcome
Screen_20Shot_202020-07-05_20at_2010_edi

Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2022, moving towards broad patient access to cancer-defeating cures."

Dr. Daniel Teper,

Cytovia Therapeutics CEO

Cytovia Therapeutics: An NK Revolution Towards a Cancer Cure
05:50
From Vision to Execution: Cytovia at a Strategic Inflection Point
03:36
Introducing Our New R&D Center of Excellence (With CSO Dr. Wei Li)
03:10
A Conversation with Board Director Michael Friedman, MD
05:30
A Conversation With Scientific Advisor Michael Caligiuri, MD
08:41
A Conversation with Scientific Advisor Justin Eyquem, PhD
06:16
A Conversation with Board Directors Laurent Audoly, PhD & Leila Alland, MD
06:47
A Conversation With Chief Scientific Officer Wei Li, PhD
06:20
bottom of page